Source Anti-Malarial Artemether Lumefantrine Tablet for Adults Children Elderly

Strategic Sourcing Guide for Anti-Malarial Artemether Lumefantrine Tablets

Understanding Product Specifications and Formulation Variants

When sourcing anti-malarial medications, specifically the combination of artemether and lumefantrine, buyers must first navigate a complex landscape of technical specifications. The core product is a solid-state tablet designed for oral administration, primarily targeting the treatment of malaria caused by Plasmodium falciparum. Based on available market data, the formulation is derived through chemical synthesis, ensuring a consistent molecular structure essential for therapeutic efficacy. However, the specific dosage strengths vary significantly across different product models, which directly impacts procurement strategy.

The observed product models indicate distinct strength profiles tailored for different patient demographics. For adult populations, the standard formulation often involves a higher dosage ratio, such as 80mg of artemether combined with 480mg of lumefantrine per tablet. In contrast, pediatric formulations are engineered with lower dosages, such as 20mg of artemether and 120mg of lumefantrine, to ensure safety and appropriate therapeutic levels for children. Some listings also reference intermediate strengths like 40mg plus 240mg, providing flexibility for specific weight-based dosing protocols. It is critical for buyers to verify the exact milligram strength required for their target market, as the packaging and labeling must align precisely with these specifications.

Packaging configurations are equally variable and depend on the intended distribution channel. The data indicates that products are commonly supplied in boxes containing specific counts, such as 6 tablets per box, 24 tablets per box, or 18 tablets per box. These inner boxes are often further consolidated into larger cartons for shipping. The "6's/box" configuration is frequently observed, while other models may utilize "24's/box" or "18 Tablets Per Box" arrangements. Buyers must confirm whether the packaging is designed for retail dispensing or bulk hospital administration, as this influences the unit cost and logistics requirements. Additionally, the product is available in a solid state, though some raw material listings may reference powder forms, necessitating a clear distinction between finished pharmaceutical products and raw active ingredients during the inquiry process.

Regulatory Compliance and Certification Verification

Navigating the regulatory environment is paramount when importing pharmaceuticals, particularly those classified as biological products or organic chemicals used for internal medicine. The primary certification observed in the market for these tablets is Good Manufacturing Practice (GMP). This certification is a non-negotiable baseline for any legitimate supplier, indicating that the manufacturing facility adheres to strict quality control standards regarding hygiene, process validation, and personnel training. Buyers should not assume that all listed products possess this status; it must be explicitly verified through current documentation.

Beyond GMP, the product standards referenced in the market include the British Pharmacopoeia (BP) and the Chinese Pharmacopoeia (CP). Some listings also mention the United States Pharmacopeia (USP) or a combined B.P./USP standard. These pharmacopoeial standards define the purity, potency, and quality attributes of the active pharmaceutical ingredients (APIs) and the finished tablet. When evaluating a supplier, procurement teams must request a Certificate of Analysis (CoA) that explicitly references the specific standard (e.g., BP, CP, or USP) against which the batch was tested. The absence of a specific standard reference in the product listing should trigger a deeper audit, as compliance with international standards is often a prerequisite for importation into regulated markets.

Registration availability is another critical compliance factor. The data indicates that product registration is available, but this is a dynamic status that varies by country. A supplier may have registration in the country of origin (China) but lack the necessary approvals for the destination market. Buyers must distinguish between the supplier's ability to provide registration documents and the actual legal status of the product in the target jurisdiction. For instance, while a product may be listed as "Treat Malaria" or "Anti-Malarial," this functional claim does not equate to regulatory approval for sale in a specific region. Procurement teams must verify that the specific product model, such as AMC12005-03 or AMC12005-08, holds the necessary registration certificates for the intended market of distribution.

Cost Drivers and Economic Parameters

The economic landscape for sourcing artemether lumefantrine tablets is influenced by several distinct factors, primarily driven by the scale of the order and the complexity of the manufacturing process. The observed Minimum Order Quantity (MOQ) ranges from 5,000 boxes to 1,000,000 units, creating a significant barrier to entry for small-scale buyers. This wide range suggests that unit costs are highly sensitive to volume; larger orders typically benefit from economies of scale, reducing the per-unit price, while smaller orders may face premium pricing or may not be accommodated at all.

The price range observed in the market is extremely narrow, listed between $0.01 and $1.00 USD. While this range indicates a competitive market, it also highlights the risk of price volatility or the inclusion of different packaging configurations within the same price bracket. A price at the lower end of this spectrum might correspond to bulk raw materials or specific high-volume packaging, whereas the higher end could reflect finished, branded, or certified products with complex logistics. Buyers must be cautious not to equate a low price with high quality; the cost must be evaluated in conjunction with the MOQ, certification status, and packaging requirements.

Lead times are another significant cost driver, with delivery times typically ranging from 30 to 60 days. This timeframe encompasses production, quality control testing, and international shipping. For buyers operating in regions with urgent malaria outbreaks, a 60-day lead time may be insufficient, necessitating the identification of suppliers with faster turnaround capabilities or the maintenance of strategic stockpiles. The transportation method, identified as "Shipping," further influences the final landed cost, as ocean freight rates, insurance, and customs duties can vary widely. Additionally, the availability of OEM/ODM support allows for customization, which may incur additional costs for mold development, label design, and packaging adjustments. Buyers should factor these potential variable costs into their total cost of ownership calculations rather than focusing solely on the base unit price.

Typical Applications and Target Demographics

The application of artemether lumefantrine tablets is primarily focused on the treatment of malaria, a disease that disproportionately affects specific demographic groups. The product is indicated for use in internal medicine, with specific suitability for adults, children, and the elderly. This broad applicability requires a diversified procurement strategy that accounts for different dosage requirements across age groups. Pediatric applications are particularly critical, as children are at higher risk for severe malaria complications. The availability of lower dosage strengths, such as 20mg+120mg, specifically targets the pediatric population, ensuring that young patients receive the correct therapeutic dose without the risk of overdose associated with adult formulations.

The product is also suitable for elderly patients, who may have different metabolic rates or comorbidities that require careful dosing. The "Paediatrics" and "Internal Medicine" application tags confirm that the product is designed for systemic treatment of the infection rather than topical or external use. In humanitarian contexts, the versatility of the product allows for a single supply chain to serve multiple demographics, provided the correct dosage strengths are procured. For example, a procurement team managing a relief effort might need to order a mix of 80mg+480mg tablets for adults and 20mg+120mg tablets for children to ensure comprehensive coverage.

Storage requirements also play a role in the application logistics. The product must be stored in a cool and dry place to maintain stability and efficacy over its shelf life, which is typically 3 years or 36 months. This storage requirement necessitates cold chain or climate-controlled logistics, particularly in tropical regions where malaria is endemic. Buyers must ensure that their distribution partners have the infrastructure to maintain these conditions from the point of manufacture to the final point of administration. Failure to adhere to storage guidelines can lead to product degradation, rendering the medication ineffective and potentially hazardous.

Supplier Evaluation and Quality Control Protocols

Evaluating suppliers for anti-malarial tablets requires a rigorous due diligence process that goes beyond basic product listings. The presence of OEM/ODM support indicates that suppliers are capable of customization, but this capability must be balanced with their ability to maintain consistent quality. Buyers should prioritize suppliers who demonstrate a robust quality management system, evidenced by their GMP certification and adherence to recognized pharmacopoeial standards. The ability to provide detailed test results and batch-specific documentation is a key indicator of a reliable supplier.

Quality control protocols should be verified at multiple stages of the supply chain. This includes pre-shipment inspections, third-party laboratory testing, and ongoing monitoring of the manufacturing process. Buyers should request samples for independent testing to verify the dissolution rate, potency, and impurity profiles of the tablets. The "Chemical Synthesis" process used for these products requires strict control over reaction conditions and purification steps to ensure the final product meets the specified standards. Any deviation in the synthesis process could lead to the presence of harmful impurities or inconsistent dosing.

Furthermore, the supplier's track record in delivering on time and maintaining stock levels is crucial. With lead times of 30 to 60 days, any disruption in the supply chain can have severe consequences for malaria treatment programs. Buyers should assess the supplier's capacity to handle large orders, as evidenced by the high MOQs observed in the market. A supplier that can consistently meet the 5,000 to 1,000,000 box range demonstrates the operational scale necessary for reliable supply. Additionally, the supplier's location in China should be considered in the context of geopolitical stability and logistics efficiency, ensuring that shipping routes remain open and reliable.

Long-Term Procurement and Strategic Considerations

Sourcing anti-malarial tablets is not merely a transactional activity but a strategic initiative that requires long-term planning. The shelf life of 3 years provides a window for inventory management, but buyers must implement a "first-expiry-first-out" (FEFO) strategy to minimize waste. Given the variability in packaging sizes, such as 6's/box, 24's/box, or 18 tablets per box, buyers should align their order quantities with their projected consumption rates to avoid overstocking or stockouts. The ability to customize packaging through OEM/ODM services allows for the creation of region-specific packaging that may include local language instructions or specific regulatory markings, enhancing the product's usability and compliance in the target market.

The market's reliance on chemical synthesis and the availability of biological products as a category highlight the need for continuous innovation and quality improvement. Buyers should engage with suppliers who are committed to ongoing research and development, ensuring that their formulations remain competitive and effective against evolving malaria strains. The availability of registration support is also a long-term consideration, as regulatory landscapes change frequently. A supplier who can assist with the registration process in the target country adds significant value, reducing the time and cost associated with market entry.

Finally, the procurement strategy must be flexible enough to adapt to fluctuations in demand, particularly during malaria outbreaks. The wide MOQ range allows for scalability, but buyers must maintain strong relationships with suppliers to secure priority production slots during peak demand periods. By focusing on technical specifications, compliance, cost drivers, and supplier reliability, buyers can build a resilient supply chain that ensures the consistent availability of life-saving anti-malarial medications. The integration of these factors into a comprehensive sourcing plan is essential for mitigating risks and ensuring the successful delivery of healthcare products to those in need.